The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAYVIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
US Federal Register - FDA Notices · August 10, 2026
Determination of Regulatory Review Period for Purposes of Patent Extension; DAYVIGO
Published by US Federal Register - FDA Notices. HealthSignal links to the original document; the summary above is extracted from the source text.